Browse the corpus

Superficial dermal infection: Topical ointment/powder: Apply to affected area 1-4 times/day; may cover with sterile bandage if needed. Dosing: Pediatric (For additional information see "Bacitracin and polymyxin B: Pediatric drug information" ) Refer to adult dosing. Dosing: Geriatric Refer to adult dosing. Dosage Forms: U.S. Excipient information presented when available (limited, particularly for generics); consult specific product labeling. Ointment, ophthalmic: Bacitracin 500 units and polymyxin B 10,000 units per g (3.5 g) AK-Poly-Bac™: Bacitracin 500 units and polymyxin B 10,000 units per g (3.5 g) Polycin™: Bacitracin 500 units and polymyxin B 10,000 units per g (3.5 g) Ointment, topical: Bacitracin 500 units and polymyxin B 10,000 units per g in white petrolatum (15 g, 30 g) Polysporin®: Bacitracin 500 units and polymyxin B 10,000 units per g (0.9 g, 15 g, 30 g) Powder, topical: Polysporin®: Bacitracin 500 units and polymyxin B 10,000 units per g (10 g) Generic Equivalent Available: U.S. Yes Use Treatment of superficial infections caused by susceptible organisms Medication Safety Issues Sound-alike/look-alike issues: Betadine® may be confused with Betagan®, betaine Adverse Reactions Significant 1% to 10%: Local: Rash, itching, burning, anaphylactoid reactions, swelling, conjunctival erythema Contraindications Hypersensitivity to bacitracin, polymyxin B, or any component of the formulation Metabolism/Transport Effects None known. Drug Interactions (For additional information: Launch Lexi-Interact™ Drug Interactions Program ) BCG: Antibiotics may diminish the therapeutic effect of BCG. Risk X: Avoid combination Capreomycin: May enhance the neuromuscular-blocking effect of Polymyxin B. Risk C: Monitor therapy Colistimethate: Polymyxin B may enhance the neuromuscular-blocking effect of Colistimethate. Risk C: Monitor therapy Neuromuscular-Blocking Agents: Polymyxin B may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Risk D: Consider therapy modification Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate. Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic. Risk D: Consider therapy modification Pregnancy Risk Factor C ( show table )

Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate. Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic. Risk D: Consider therapy modification Pregnancy Risk Factor C ( show table ) Pregnancy Implications Animal reproduction studies have not been conducted with this combination. See individual agents. Lactation Excretion in breast milk unknown/use caution Breast-Feeding Considerations It is not known if bacitracin or polymyxin B are excreted into breast milk. The manufacturer recommends that caution be exercised when administering to nursing women. See individual agents. Pricing: U.S. (Medi-Span®)

Ointment (Polysporin External) 500-10000 units/g (1): $0.24 500-10000 units/g (14.2 g): $4.42 International Brand Names Glubacida (MX); Miratracina (CO); Nebacetina (MX); Neobacitracine (BE); Neosporín Dérmico (MX); Polisulfade (PT); Polixin Ungena (MX); Polyfax (MY); Polysporin Ophthalmic (ZA); Tribiot (MX) Mechanism of Action See individual agents. Pharmacodynamics/Kinetics See individual agents. Use of UpToDate is subject to the Subscription and License Agreement . Topic 9387 Version 36.0 © 2013 UpToDate, Inc. All rights reserved. | Subscription and License Agreement | Release: 21.6- C21.56 Licensed to: AsanBook Dig. Med. Lib. | Support Tag: [1104-183.1.191.153-8DAC4F1F78-S244013.14]